
SWOBY
Healthcare · Drug Manufacturers - Specialty & Generic · $16.08B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Oct 27, 2026 | Time not confirmed | — | 0.35 | — |
| Jul 16, 2026 | Time not confirmed | — | 0.17 | — |
| Apr 27, 2026 | Before the open | — | 0.21 | — |
| Feb 5, 2026 | Time not confirmed | — | 0.28 | — |
| Oct 23, 2025 | Before the open | — | -0.44 | — |
| Jul 16, 2025 | Before the open | — | 0.09 | — |
| Apr 29, 2025 | Before the open | — | 0.12 | — |
| Feb 5, 2025 | Before the open | — | 0.19 | — |
| Oct 24, 2024 | Before the open | — | 0.20 | — |
| Jul 16, 2024 | Before the open | — | 0.03 | — |
| Apr 25, 2024 | Before the open | — | 0.11 | — |
| Feb 8, 2024 | Before the open | — | 0.14 | — |
| Oct 30, 2023 | Time not confirmed | — | 0.01 | — |
| Jul 18, 2023 |
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A;…
| Time not confirmed |
| — |
| 0.03 |
| — |
| Apr 27, 2023 | Time not confirmed | — | 0.16 | — |